Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.36 |
| ▸ | ACACA | Q13085 | 11/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492036 | 0.93 | ACACB (0.34) | ACACBACACABRD4PDE4BPDE11A | |
| SCHEMBL3495144 | 0.91 | ACACB (0.46) | ACACBACACA | |
| SCHEMBL3495140 | 0.85 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL13340594 | 0.85 | ACACB (0.32) | ACACBACACA | |
| SCHEMBL3495141 | 0.85 | ACACB (0.43) | ACACBACACA | |
| SCHEMBL3494182 | 0.84 | ACACB (0.35) | ACACBACACABRD4PDE4BPDE11A | |
| SCHEMBL3494179 | 0.84 | ACACB (0.35) | ACACBACACABRD4PDE4BPDE11A | |
| SCHEMBL3492640 | 0.83 | ACACB (0.48) | ACACBACACA | |
| SCHEMBL3492638 | 0.83 | ACACB (0.48) | ACACBACACA | |
| SCHEMBL3494270 | 0.81 | ACACB (0.32) | ACACBACACAPDE4BPDE11APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | ACACB 5/4885ACACA 1/4885BRD4 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.